Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I remember someone posted link to the contract of one hospital in Sardynia using Ncyt technoloy worth circa 1.5 mln Euro . Asking at the end what if ncyt can supply few hundred such hospitals.
what about sells to foreign countries ???? All analyses are based on uk !!!!!!!!!!!
70% efficacy . Is that good ???????
From the half year's results : The Directors reiterate guidance announced on 13 July 2020; given the visibility of orders, extended contracts and the launch of new COVID-19 related products, revenue for the second half of the year is expected to be greater than the first half of the year and margins to be at least at a similar level. Full year revenues are expected to exceed €150 million and EBITDA profitability to exceed €100 million. The Company expects this rate of financial performance to extend into the first half of 2021. The Directors remain confident in and excited by the prospects of the business, not only for the short-term, but also for the longer-term.
And afterwards he have had DHSC contract and info about five-fold increase in pcr machine production.
£2b ????!!!!!!!!!!!!!
Yeah , just that we bit expectations .
ALTHOUGH DELAYS TO vaccines are common,
given the positive slew of positive news over
the last few weeks the three-month delay to the
possible market launch of the GlaxoSmithKline
(GSK) vaccine candidate (in partnership with
Sanofi) was unfortunate.
The two companies now plan a new study
GLAXOSMITHKLINE
(GSK) £14.00
NOVACYT
(NCYT:AIM) 870.2p
Gain to date: 6%
Original entry point:
Buy at £13.21, 5 November 2020
Gain to date: 37.7%
Original entry point:
Buy at 632p, 8 October 2020
SHARES SAYS: ?
Despite somewhat divergent fortunes of late these
are both still buys. [MG]
starting in February with an improved
formulation which will include a comparison
with an authorized Covid-19 vaccine.
If the data from the trial is as hoped, a final
trial will begin in the second quarter. Positive
results from this trial would then lead to
regulatory submissions in the second half of
2021, delaying the vaccine’s potential availability
from mid-year to the final quarter.
Importantly there are no significant financial
implications attached to the delay.
In a more positive Covid-linked corporate
development Novacyt (NCYT:AIM) added to its
diagnostic capabilities with the launch of a test
(14 Dec) for the mutation of the Covid-19 virus
associated with Danish Minks.
The mutation is of concern to scientists
because it causes an amino acid change which
affects antibody binding. The launch of the test
puts Novacyt in a strong position should the need
arise to differentiate the new strain.
Exactly
Lets hope in others countries authorities see which test is better.
Sorry . But where is novacyt mentioned in this info.
162 people got placebo out of 170 people who contracted . 162 / 170 = 0.95 so 95% efficacy .
Proper **** , terrifying : Pfizer and BioNTech have not yet made the data from the late-stage trial fully available to the public but have said an analysis of early data found the vaccine to be 95% effective and to show signs of being safe. However, the initial data covered just 170 adult volunteers in a trial involving nearly 44,000 people, and only eight of those actually got the vaccine, with the remaining 162 getting the placebo.
https://www.cityam.com/pfizer-given-protection-from-legal-action-by-uk-government/
The government has granted Covid-19 manufacturer Pfizer a legal indemnity protecting it from being sued, enabling its coronavirus vaccine to be rolled out across the country as early as next week.
The Department of Health and Social Care has confirmed the company has been given an indemnity protecting it from legal action as a result of any problems with the vaccine, the Independent reported.
Read more: Pfizer vaccine to be rolled out across 50 hospital hubs from next week
The Pfizer/BioNTech vaccine was approved for use in the UK, with roll out planned for early next week, becoming the first Western country to approve a vaccine.
NHS staff providing the vaccine, as well as manufacturers of the drug, are also protected.
Read more: Pfizer vaccine: Matt Han**** green-lights 800,000 doses for rollout next week
In a press conference with journalists on Wednesday, Ben Osborn, Pfizer’s UK managing director, refused to explain why the company needed an indemnity.
He said: “We’re not actually disclosing any of the details around any of the aspects of that agreement and specifically around the liability clauses.”
Read more: ‘No corners have been cut’: UK’s top scientists ward off anti-vaxxers with vaccine rollout plan
Around 50 hospital hubs around England will start offering the Pfizer vaccine to patients and staff in care homes from next week.
The NHS will also start sending letters out next week inviting vulnerable members of the population to go and get a vaccine from a designated hospital.
The Pfizer/Biontech vaccine, which comes in packs of 975 doses, will first be given to the most vulnerable Brits, going down the generational chart.
and more spreading
Yeah,the bood is boiling .
This contract is for 406 mln for 4 months until 28 Jan . , so £300 mln will fall into 2020 .
Publication date 2 April 2020 .
Stand to corrected on the deal value with DHSC ( did not think at time of writing) , but romanian deal also requires assays and kit .
Someone posted that Ncyt sold 1425 machine for circa £2 mln to Romania . So why 300 machine sold to government raised £470 mln ????